Compare KVYO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KVYO | NUVL |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.1B |
| IPO Year | 2023 | 2021 |
| Metric | KVYO | NUVL |
|---|---|---|
| Price | $28.54 | $104.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 23 | 15 |
| Target Price | $42.83 | ★ $135.00 |
| AVG Volume (30 Days) | ★ 3.0M | 531.0K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,153,988,000.00 | N/A |
| Revenue This Year | $32.38 | N/A |
| Revenue Next Year | $21.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.81 | N/A |
| 52 Week Low | $23.44 | $55.54 |
| 52 Week High | $49.55 | $112.88 |
| Indicator | KVYO | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 53.77 |
| Support Level | $27.87 | $95.51 |
| Resistance Level | $30.06 | $108.46 |
| Average True Range (ATR) | 1.35 | 3.91 |
| MACD | -0.52 | -0.01 |
| Stochastic Oscillator | 21.16 | 71.75 |
Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.